Welcure Drugs

Why is Welcure Drugs & Pharmaceuticals Ltd falling/rising?

As of 01-Sep, Welcure Drugs & Pharmaceuticals Ltd's stock price has risen to 0.25, reflecting a 4.17% increase. This growth is driven by strong relative performance, increased investor interest, and a positive trend over the past few days, despite being below longer-term moving averages.

As of 01-Sep, Welcure Drugs & Pharmaceuticals Ltd is experiencing a rise in its stock price, currently at 0.25, which reflects a change of 0.01 or an increase of 4.17%. This upward movement can be attributed to several factors. <BR><BR>Firstly, the stock has outperformed the sector by 4.77% today, indicating strong relative performance. Additionally, it has been on a positive trend, gaining for the last three consecutive days and achieving a total return of 25% during this period. The stock's performance over the past week shows a significant increase of 19.05%, contrasting sharply with the Sensex, which has declined by 0.92%.<BR><BR>Moreover, there has been a notable increase in investor participation, with a delivery volume of 55.24 lacs on August 31, which is up by 35.75% compared to the five-day average. This suggests growing interest and confidence among investors. <BR><BR>While the stock is currently trading higher than its 5-day, 20-day, and 50-day moving averages, it remains below the 100-day and 200-day moving averages, indicating potential for further growth. Overall, the combination of strong recent performance, increased investor activity, and positive sector comparison contributes to the rising stock price of Welcure Drugs & Pharmaceuticals Ltd.

Who are in the management team of Welcure Drugs?

The management team of Welcure Drugs includes D C Jain (Non-Executive Director), Sudhir Chandra (Managing Director), Mitashi Bisaria (Director & Company Secretary), Gagan Juneja (Independent Director), Mohd. Shahbaz Alam (Independent Director), Sitaben S Patel (Additional Director), and Rajeev Mehra (Additional Director).

The management team of Welcure Drugs includes the following members:<BR><BR>1. **D C Jain** - Non-Executive & Non-Independent Director<BR>2. **Sudhir Chandra** - Managing Director<BR>3. **Mitashi Bisaria** - Director & Company Secretary<BR>4. **Gagan Juneja** - Non-Executive & Independent Director<BR>5. **Mohd. Shahbaz Alam** - Independent Director<BR>6. **Sitaben S Patel** - Additional Director<BR>7. **Rajeev Mehra** - Additional Director<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

What does Welcure Drugs do?

Welcure Drugs & Pharmaceuticals Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 1992, with a recent net profit of -50 Cr for March 2026 and a market cap of INR 27 Cr. Key metrics include a P/E of 1.00, a debt-equity ratio of -0.01, and a return on equity of 36.50%.

Overview: <BR>Welcure Drugs & Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>Incorporated on 4th June, 1992, Welcure Drugs And Pharmaceuticals Limited was promoted by D C Jain, Sanjeev Jain, and Sandeep Jain. The latest quarterly results reported a net profit of -50 Cr for March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: -50 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 27 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 1.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.01 <BR>Return on Equity: 36.50% <BR>Price to Book: 0.28<BR><BR>Contact Details: <BR>Address: B-9 & 10 Laxmi Towers, L S C Block-C Saraswati Vihar Delhi New Delhi : 110034 <BR>Tel: 91-011-2701 1428 <BR>Email: investor.welcure@gmail.com <BR>Website: https://welcuredrugs.com

Who are the peers of the Welcure Drugs?

Welcure Drugs' peers include Lasa Supergeneri, Guj. Terce Labs., Medi Caps, and others. Management risk is average for Welcure Drugs, with below-average growth and a return of -72.73%, while Cian Healthcare leads in returns at 252.28%.

Peers: The peers of Welcure Drugs are Lasa Supergeneri, Guj. Terce Labs., Medi Caps, Cian Healthcare, Venmax Drugs, Ishita Drugs, Centuple Global, Shree Ganesh Bio, Colinz Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Centuple Global, while Average management risk is found at Welcure Drugs and the rest. Below Average management risk is noted for Lasa Supergeneri, Guj. Terce Labs., Medi Caps, Cian Healthcare, Venmax Drugs, Ishita Drugs, Shree Ganesh Bio, Colinz Labs, and Medicamen Organ. Growth is Average at Guj. Terce Labs. and Venmax Drugs, while Below Average growth is seen at Welcure Drugs, Lasa Supergeneri, Medi Caps, Cian Healthcare, Ishita Drugs, Shree Ganesh Bio, Colinz Labs, and Medicamen Organ. Good capital structure is noted for Medi Caps, Welcure Drugs, Ishita Drugs, Shree Ganesh Bio, and Colinz Labs, while Average capital structure is found at Lasa Supergeneri and Below Average at Guj. Terce Labs., Cian Healthcare, Venmax Drugs, and Medicamen Organ.<BR><BR>Return Snapshot: Cian Healthcare has the highest 1-year return at 252.28%, while Medi Caps has the lowest at -35.44%, with Welcure Drugs' return at -72.73% being significantly lower than both. Additionally, the six-month return is negative for Lasa Supergeneri, Venmax Drugs, Ishita Drugs, Centuple Global, Shree Ganesh Bio, and Medicamen Organ.

Which are the latest news on Welcure Drugs?

How big is Welcure Drugs?

Summary could not be generated.

As of 14th August, <BR><BR>Market Cap: Welcure Drugs & Pharmaceuticals Ltd has a market capitalization of 29.66 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 365.53 Cr, while the sum of Net Profit for the same period shows a loss of 16.99 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is the latest annual period, but data for Shareholder's Funds and Total Assets is unavailable.

Should I buy, sell or hold Welcure Drugs & Pharmaceuticals Ltd?

Are Welcure Drugs & Pharmaceuticals Ltd latest results good or bad?

Welcure Drugs & Pharmaceuticals Ltd's latest results are concerning, showing a 100% decline in net sales to ₹0.00 and an operating margin drop to 0.0%. The reported net profit of ₹1.07 crores was misleading, driven entirely by non-operating income, indicating serious operational distress and risks to future viability.

The latest results for Welcure Drugs & Pharmaceuticals Ltd are concerning and indicate significant operational distress. In Q3 FY26, the company reported net sales of ₹0.00, marking a dramatic 100% decline from the previous quarter. This is alarming as it suggests a complete cessation of commercial operations. <BR><BR>While the company reported a net profit of ₹1.07 crores, this figure is misleading as it was primarily driven by other income of ₹1.46 crores, which accounted for over 100% of the profit before tax. The core pharmaceutical business did not contribute to profitability, indicating serious issues with its operational viability.<BR><BR>The operating margin has also dropped to 0.0%, down from 17.31% in the previous quarter, highlighting a severe decline in operational performance. The return on equity (ROE) of 33.54% appears high but is not reflective of sustainable business operations, given the lack of revenue generation.<BR><BR>Overall, the results suggest a troubling situation for Welcure Drugs, with significant risks regarding its future viability and operational continuity. Investors should approach this stock with caution, as the combination of zero revenue and reliance on non-operating income raises serious red flags about the company's financial health.

How has been the historical performance of Welcure Drugs?

Welcure Drugs experienced a significant turnaround in the fiscal year ending March 2025, reporting net sales of 24.55 crore and a profit after tax of 2.17 crore, compared to losses in the previous year. This marked its first year of substantial revenue generation and profitability, with improved operating and profit margins.

Answer:<BR>The historical performance of Welcure Drugs shows significant changes, particularly in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Welcure Drugs reported net sales of 24.55 crore, a notable increase from previous years where sales were non-existent. The total operating income also rose to 24.55 crore, reflecting the same trend. The company's total expenditure, excluding depreciation, was recorded at 23.67 crore, which is a substantial increase from 0.23 crore in March 2024. Operating profit (PBDIT) for March 2025 was 2.79 crore, a recovery from a loss of 0.14 crore in the previous year. Profit before tax reached 2.78 crore, compared to a loss of 0.17 crore in March 2024, leading to a profit after tax of 2.17 crore, up from a loss of 0.17 crore. The earnings per share (EPS) improved to 0.02 from a negative 0.13 in the prior year, indicating a positive shift in profitability. The operating profit margin for March 2025 was 3.58%, and the profit after tax margin stood at 8.84%, both reflecting a strong performance compared to the previous years where these metrics were at zero. Overall, the financial results for March 2025 demonstrate a significant turnaround for Welcure Drugs, marking its first year of substantial revenue generation and profitability.

What is the bonus history of Welcure Drugs?

Welcure Drugs has announced a 1:10 bonus issue, with an ex-date and record date set for October 16, 2025. Shareholders will receive 1 additional share for every 10 shares held.

Welcure Drugs has a recent bonus issue history where they announced a 1:10 bonus issue. The ex-date for this bonus is set for October 16, 2025. This means that for every 10 shares held, shareholders will receive 1 additional share as a bonus. The record date for this bonus is also October 16, 2025. If you have any more questions about Welcure Drugs or need further details, feel free to ask!

Is Welcure Drugs overvalued or undervalued?

As of September 15, 2025, Welcure Drugs is considered an attractive investment due to its low PE ratio of 3.41 and significant undervaluation compared to peers like Sun Pharma and Divi's Lab, despite a year-to-date return of -28.11%.

As of 15 September 2025, the valuation grade for Welcure Drugs has moved from very attractive to attractive. The company is currently considered undervalued, given its low PE ratio of 3.41, a price-to-book value of 0.92, and an EV to EBITDA of 6.45. These ratios indicate that the stock is trading at a significant discount compared to its earnings and book value.<BR><BR>In comparison to its peers, Welcure Drugs stands out with a much lower PE ratio than Sun Pharma (33.52) and Divi's Lab (69.55), both of which are classified as expensive. Additionally, its PEG ratio of 0.01 further emphasizes its undervaluation relative to the industry. Despite recent stock performance trailing the Sensex, particularly with a year-to-date return of -28.11% compared to the Sensex's 4.67%, the fundamental metrics suggest that Welcure Drugs presents a compelling investment opportunity at its current price.

When is the next results date for Welcure Drugs?

Welcure Drugs will announce its results on 05 August 2025.

Welcure Drugs will declare its results on 05 August 2025.

Who are the top shareholders of the Welcure Drugs?

The top shareholders of Welcure Drugs are primarily individual investors, holding 98.99% of the shares, with Rahul Ratansingh Sikarwar being the largest individual shareholder at 9.78%. There are no institutional investors or pledged promoter holdings.

The top shareholders of Welcure Drugs primarily consist of individual investors, who hold a significant 98.99% of the company's shares. Among public shareholders, the highest individual shareholder is Rahul Ratansingh Sikarwar, with a holding of 9.78%. There are no institutional investors or mutual funds currently holding shares in the company, and there are no pledged promoter holdings.

What is the technical trend for Welcure Drugs?

As of May 8, 2025, Welcure Drugs shows a bullish technical trend supported by strong MACD, Bollinger Bands, and moving averages, though caution is advised due to a mildly bullish weekly Dow Theory trend.

As of 8 May 2025, the technical trend for Welcure Drugs has changed from mildly bullish to bullish. The weekly and monthly MACD are both bullish, indicating strong momentum. Bollinger Bands also reflect a bullish stance on both time frames. Daily moving averages are bullish, supporting the upward trend. The KST is bullish on both weekly and monthly charts, further confirming the positive outlook. However, the Dow Theory shows a mildly bullish trend on the weekly but no trend on the monthly, suggesting some caution. Overall, the current technical stance is bullish with strong indicators supporting this view.

Has Welcure Drugs declared dividend?

No Dividend History Available